Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Press

Showing results (101-110 of 273) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2013
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.
Journal of Cancer|January 27, 2017
Human-derived normal mesenchymal stem/stromal cells in anticancer therapiesCheng Zhang, Shi-Jie Yang, Qin Wen, et al.
Oncology Reports|April 4, 1998
Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samplesS Wang-Gohrke, S Hees, A Pochon, et al.
Plos One|May 5, 2021
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapyJason J Zoeller, Michael F Press, Laura M Selfors, et al.
Annals of Surgical Oncology|June 6, 2018
RNA-Seq of Circulating Tumor Cells in Stage II-III Breast CancerJulie E Lang, Alexander Ring, Tania Porras, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 26, 1999
MDR1 gene expression in primary and advanced breast cancerX Yang, B Uziely, S Groshen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 20, 2012
Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decadesReina Haque, Syed A Ahmed, Galina Inzhakova, et al.
Science (New York, N.Y.)|January 30, 1970
Passive seismic experimentG V Latham, M Ewing, F Press, et al.
Breast Cancer Research and Treatment|September 27, 2005
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumabNoël Dybdal, Grazyna Leiberman, Steven Anderson, et al.
Pageof 28

Showing results (101-110 of 273) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2013
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.
Journal of Cancer|January 27, 2017
Human-derived normal mesenchymal stem/stromal cells in anticancer therapiesCheng Zhang, Shi-Jie Yang, Qin Wen, et al.
Oncology Reports|April 4, 1998
Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samplesS Wang-Gohrke, S Hees, A Pochon, et al.
Plos One|May 5, 2021
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapyJason J Zoeller, Michael F Press, Laura M Selfors, et al.
Annals of Surgical Oncology|June 6, 2018
RNA-Seq of Circulating Tumor Cells in Stage II-III Breast CancerJulie E Lang, Alexander Ring, Tania Porras, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 26, 1999
MDR1 gene expression in primary and advanced breast cancerX Yang, B Uziely, S Groshen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 20, 2012
Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decadesReina Haque, Syed A Ahmed, Galina Inzhakova, et al.
Science (New York, N.Y.)|January 30, 1970
Passive seismic experimentG V Latham, M Ewing, F Press, et al.
Breast Cancer Research and Treatment|September 27, 2005
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumabNoël Dybdal, Grazyna Leiberman, Steven Anderson, et al.
Pageof 28